The newly issued shares of the Krakow-based Selvita were promptly sold. Investors declared to buy the whole offering at the maximum price. Some even wanted more. This will be a solid capital inflow for the company. Selvita laboratories have already developed a potential medicine currently administered to patients in the US.
The firm was Selvita’s legal adviser.